Dental and bunion surgeries were the targets of the clinical trials and the drug was tolerated well.  BD

The Food and Drug Administration has given Xanodyne Pharmaceuticals the go-ahead to market its Zipsor prescription pain reliever in a liquid-filled capsule, the company said Wednesday.image

Zipsor, a non-steroidal anti-inflammatory drug, was shown to be effective at a low dose (25 mg), in trials involving post-surgical pain treatment after bunionectomies.


Xanodyne wins FDA approval for Zipsor capsules - Business Courier of Cincinnati:


Post a Comment

Google Analytics Alternative